Education
About Us
Working with TipRanks
Follow Us
Integrated BioPharma Inc (INBP)
OTHER OTC:INBP
Total Valuation
Integrated BioPharma has a market cap or net worth of $9.16M. The enterprise value is $8.33M.
Market Cap$9.16M
Enterprise Value$8.33M
Share Statistics
Integrated BioPharma has 31,059,610 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,059,610
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Integrated BioPharma’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 3.71%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)3.71%
Return on Capital Employed (ROCE)0.10
Revenue Per Employee369.75K
Profits Per Employee5.50K
Employee Count147
Asset Turnover2.18
Inventory Turnover5.21
Valuation Ratios
The current PE Ratio of Integrated BioPharma is 12.1. Integrated BioPharma’s PEG ratio is 0.02.
PE Ratio12.1
PS Ratio0.20
PB Ratio0.53
Price to Fair Value0.53
Price to FCF5.77
Price to Operating Cash Flow4.75
PEG Ratio0.02
Income Statement
In the last 12 months, Integrated BioPharma had revenue of 54.35M and earned 808.00K in profits. Earnings per share was 0.03.
Revenue54.35M
Gross Profit5.56M
Operating Income2.02M
Pretax Income2.06M
Net Income808.00K
EBITDA3.38M
Earnings Per Share (EPS)0.03
Cash Flow
In the last 12 months, operating cash flow was 2.06M and capital expenditures -205.00K, giving a free cash flow of 1.86M billion.
Operating Cash Flow2.06M
Free Cash Flow1.86M
Free Cash Flow per Share0.06
Dividends & Yields
Integrated BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.27
52-Week Price Change24.00%
50-Day Moving Average0.28
200-Day Moving Average0.31
Relative Strength Index (RSI)57.41
Average Volume (3m)10.87K
Important Dates
Integrated BioPharma upcoming earnings date is Nov 6, 2025, After Close (Confirmed).
Last Earnings DateSep 23, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date―
Financial Position
Integrated BioPharma as a current ratio of 4.42, with Debt / Equity ratio of 5.00%
Current Ratio4.42
Quick Ratio2.21
Debt to Market Cap0.09
Net Debt to EBITDA-0.77
Interest Coverage Ratio43.91
Taxes
In the past 12 months, Integrated BioPharma has paid 1.25M in taxes.
Income Tax1.25M
Effective Tax Rate0.61
Enterprise Valuation
Integrated BioPharma EV to EBITDA ratio is 2.43, with an EV/FCF ratio of 4.38.
EV to Sales0.15
EV to EBITDA2.43
EV to Free Cash Flow4.38
EV to Operating Cash Flow3.98
Balance Sheet
Integrated BioPharma has $3.62M in cash and marketable securities with $1.01M in debt, giving a net cash position of $2.60M billion.
Cash & Marketable Securities$3.62M
Total Debt$1.01M
Net Cash$2.60M
Net Cash Per Share$0.08
Tangible Book Value Per Share$0.67
Margins
Gross margin is 10.23%, with operating margin of 3.72%, and net profit margin of 1.49%.
Gross Margin10.23%
Operating Margin3.72%
Pretax Margin3.79%
Net Profit Margin1.49%
EBITDA Margin6.21%
EBIT Margin3.88%
Analyst Forecast
The average price target for Integrated BioPharma is $0.50, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$0.50
Price Target Upside61.29% Upside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast8.02%
EPS Growth Forecast624.32%